New medications for treatment of systemic mycoses;Neue medikamente zur behandlung systemischer mykosen

Internist

Volumn 46, Issue 6, 2005, Pages 659-670

  Schedel, I ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antiinfective treatment; Antimycotics; Echinocandins; Fungal infection; Triazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CISPLATIN; CLOTRIMAZOLE; COLISTIN; CYCLOSPORIN; DIURETIC AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TACROLIMUS; TRIAZOLE; VANCOMYCIN; VORICONAZOLE;

AREA UNDER THE CURVE; ARTICLE; BRONCHOPULMONARY ASPERGILLOMA; CANDIDIASIS; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LUNG INFECTION; MUCORMYCOSIS; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PNEUMONIA; RISK ASSESSMENT; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMANS; MYCOSES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 21344441915     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1413-x     Document Type: Article

References (30)

1. Ally R, Schurmann D, Kreisel W (2001) A randomized, doublesive aspergillosis (IA) caused by Aspergillus terreus: multi- blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447-1454
2. Antachopoulos C, Walsh TJ (2005) New agents for invasive mycoses in children. Curr Opin Pediatr 17:78-87
3. Arathoon EG (2001) Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 14:685-691
4. Arathoon EG, Gotuzzo E, Noriega LM et al. (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 46:451-457
5. Bachmann SP, Patterson TF, Lopez-Ribot JL (2002) In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40:2228-2230
6. Baden LR, Katz JT, Fishman JA (2003) Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76:1632-1637
7. Como JA, Dismukes WE (1994) Oral azole drugs as systemic antifungal therapy. N Engl J Med 330(4):263-272
8. Denning DW (1997) Echinocandins and pneumocandins - a new antifungal class with a novel mode of action (1997). J Antimicrob Chemother 40:611-614
9. Denning DW, Ribaud P, Milpied N (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571
10. Eriksson U, Seifert B, Schaffner A (2001) Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial Br Med J 322:579-585
11. Gupta AK, Tomas E (2003) New antifungal agents. Dermatol Clin 21(3):565-576
12. Herbrecht R, Denning DW, Patterson TF (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
13. Horst CM van der, Saag MS, Cloud GA (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337(1):15-21
14. Larsen RA, Bozzette SA, Jones BE (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19(4):741-745
15. Laverdiere M, Hoban D, Restieri C, Habel F (2002) In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50:119-123
16. Lewis JS, Boucher HW, Lubowski T (2003) Economic advantage of voriconazole (VRC) for primary treatment of invasive aspergillosis compared to conventional amphotericin B (CAB) [abstract no. A-1359]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstracts, American Society for Microbiology; Sep 14-17; Chicago
17. Mora-Duarte J, Betts R, Rotstein C (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
18. Offner F (1997) Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis 16(1):56-63
19. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:651-655
20. Ozer H, Armitage JO, Bennett CL et al. (2000) American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18(20):3558-3585
21. Perfect JR, Marr KA, Walsh TJ (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122-1131
22. Pinner RW, Teutsch SM, Simonsen L (1996) Trends in infectious diseases mortality in the United States. JAMA 275(3):189-193
23. Stille W, Brodt HR, Groll AH, Just-Nübling G (2005) Antibiotika-Therapie, 11. Aufl. Schattaue, Stuttgart New York
24. Tietz HJ, Sterry W (2002) Antimykotika von A-Z, 2. Aufl. Blackwell Wissenschafts-Verlag, Berlin Wien
25. Ullmann AJ, Van Burik JA, McSweeney P (2003) An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Abstract 722. In: Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases 2003. Glasgow, UK
26. Villanueva A, Arathoon EG, Gottuzzo E et al. (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529-1535
27. Walsh TJ, Pappas P, Winston DJ (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225-234
28. Walsh TJ, Teppler H, Donowitz GR (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
29. Wilson LS, Reyes CM, Stolpman M et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5 (1):26-34
30. Wu JJ, Pang KR, Huang DB, Tyring SK (2004) Therapy of systemic fungal infections. Dermatol Ther 17:532-538